ArticleInfectious diseases and therapy2024
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
Wang-Da Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.